Clinical Trials Logo

Clinical Trial Summary

This is a phase II, open label, active-controlled, randomized safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Pediatric Growth Hormone Deficiency

NCT number NCT01592500
Study type Interventional
Source OPKO Health, Inc.
Contact
Status Completed
Phase Phase 2
Start date February 2012
Completion date July 2015

See also
  Status Clinical Trial Phase
Completed NCT01718041 - Versartis Trial in Children to Assess Long-Acting Growth Hormone Phase 1/Phase 2
Terminated NCT02068521 - Versartis Long-Term Safety Study of Somavaratan Phase 2/Phase 3
Not yet recruiting NCT05509894 - Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
Completed NCT04633057 - A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency Phase 3
Withdrawn NCT06113952 - A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
Active, not recruiting NCT02968004 - Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children Phase 3
Terminated NCT02413138 - Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317) Phase 2/Phase 3